Renal Academy 2008
Extending the path of care
for renal patients
Barcelona International Convention Center,
Barcelona, Spain, September 12–13, 2008
Dr Tony Besarab
Speaking about 'Erythrocyte survival, biology of erythropoiesis, Hb rise and decline'
“What physicians have to learn is that it takes a certain amount of time to make a red cell.”
 Download key slides of Dr Tony Besarab's presentation about 'Erythrocyte survival, biology of erythropoiesis, Hb rise and decline'. |  |
Video Selector
Once Monthly C.E.R.A. provides stable Hb levels in CKD patients on dialysis following direct switch from shorter acting ESAs (Poster number SA:PO2669)
- Dr Danilo Fliser
- ASN 2008
The safety profiles of ESAs at different hemoglobin levels (Poster number SA:PO2670)
- Dr Robert Provenzano
- ASN 2008
Erythrocyte survival, biology of erythropoiesis, Hb rise and decline
- Dr Tony Besarab
- Renal Academy
Post-transplant anaemia
- Dr Helio Tedesco Silva
- Renal Academy
Erythropoietin, cardiovascular biology and beyond
- Dr Pedro Aljama
- Renal Academy
C.E.R.A. has a comparable safety profile to other erythropoiesis stimulating agents (ESAs) in patients with chronic kidney disease (CKD)
- Dr Gilbert Deray
- EDTA 2008
C.E.R.A. maintains stable haemoglobin levels in dialysis patients regardless of administration route (IV or SC)
- Dr Bruce Spinowitz
- EDTA 2008
